Get the Stockscreener App
2.5395
24.70%
0.5595
Invivyd Inc stock is traded at $2.5395, with a volume of 13.44M.
It is up +24.70% in the last 24 hours and up +365.08% over the past month.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
See More
Previous Close:
$1.98
Open:
$2.001
24h Volume:
13.44M
Relative Volume:
1.16
Market Cap:
$236.84M
Revenue:
-
Net Income/Loss:
$-225.14M
P/E Ratio:
-1.2957
EPS:
-1.96
Net Cash Flow:
$-192.27M
1W Performance:
+590.27%
1M Performance:
+365.08%
6M Performance:
+146.91%
1Y Performance:
-47.69%
1-Day Range:
$1.96
$2.54
1-Week Range:
$0.4363
$2.74
52-Week Range:
$0.3546
$5.10
Invivyd Inc Stock (IVVD) Company Profile
Name
Invivyd Inc
Sector
Industry
Phone
(781) 819-0080
Address
1601 TRAPELO ROAD, WALTHAM
Compare IVVD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IVVD
Invivyd Inc
|
2.525 | 236.84M | 0 | -225.14M | -192.27M | -1.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.74 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.56 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
653.15 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.66 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.41 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-05-24 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-26-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-19-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| May-01-23 | Initiated | H.C. Wainwright | Buy |
Invivyd Inc Stock (IVVD) Latest News
Exploring High Growth Tech Stocks in the United States - Simply Wall St
Following A 407.69% Weekly Incline, Is It Still A Buy For Invivyd Inc (NASDAQ: IVVD)? - Marketing Sentinel
Top Small Cap Stocks Worth WatchingFebruary 03rd - MarketBeat
This Penny Stock Just Doubled on Clinical Trial Results. Analysts Think It Can Surge 266% From Here. - MSN
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga India
Invivyd (IVVD) Stock Rises Following Strategic Partnership - Stocks Telegraph
Invivyd tweaks COVID prophylactic playbook, teaming with NFL coach Jim Harbaugh for awareness drive - FiercePharma
Invivyd (NASDAQ:IVVD) Earns “Buy” Rating from HC Wainwright - Defense World
Brokers Offer Predictions for Invivyd FY2029 Earnings - Defense World
H.C. Wainwright maintains Buy rating on Invivyd stock at $10 target - MSN
Invivyd Inc Reports Q4 2024 Revenue of $13.8 Million, Slightly B - GuruFocus.com
(IVVD)Analyzing Invivyd's Short Interest - Benzinga
Invivyd Announces Partnership with Pro Football Coach Jim Harbaugh to Elevate Awareness and Ongoing Impact of COVID-19: Common, Not A Cold - The Manila Times
Analysts’ Revisions Show Improving Sentiment For Invivyd Inc (NASDAQ: IVVD) - Stocks Register
D. Boral Capital Reiterates “Buy” Rating for Invivyd (NASDAQ:IVVD) - Defense World
I See The Bull Case For Invivyd, But I’m Not Married To It (NASDAQ:IVVD) - Seeking Alpha
Invivyd Tracks SARS-CoV-2 Evolution, Prepares for Future Variants - Contagionlive.com
A Guide To The Risks Of Investing In Invivyd Inc (IVVD) - Knox Daily
Invivyd’s Promising Developments in COVID-19 Therapeutics Support Buy Rating - TipRanks
HC Wainwright Reiterates "Buy" Rating for Invivyd (NASDAQ:IVVD) - MarketBeat
It makes sense and dollars to buy Invivyd Inc (IVVD) stock - SETE News
Invivyd Shares Soar Premarket After Tripling Monday Following Initial Results From COVID-19 Vaccination Alternative - Marketscreener.com
Invivyd, Inc. (NASDAQ:IVVD) Sees Large Increase in Short Interest - Defense World
Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
Why Invivyd Inc (IVVD) Is Skyrocketing So Far In 2025 - Insider Monkey
News on Alternative monoclonal antibody for treatment of COVID-19 Spikes Invivyd, Inc. (Nasdaq: IVVD) to Top Gainer List - Investorideas.com newswire
A closer look at IVVD’s price-to-free cash flow ratio - US Post News
Invivyd Touts Encouraging Data From COVID-19 Antibody Trial, Stock Jumps - Benzinga
Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability - The Manila Times
Invivyd Announces Positive Phase 1/2 Clinical Data for - GlobeNewswire
Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates - EIN News
Will Invivyd (NASDAQ:IVVD) Spend Its Cash Wisely? - Simply Wall St
Invivyd Inc (IVVD) Volatility Hits 11.66% – Here Is What You Should Do - Stocks Register
Adagio Therapeutics stock hits 52-week low at $0.38 - Investing.com
We Might See A Profit From Invivyd, Inc. (NASDAQ:IVVD) Soon - Yahoo Finance
Invivyd seeks FDA nod for COVID-19 treatment in immunocompromised - MSN
Invivyd’s (IVVD) Buy Rating Reaffirmed at D. Boral Capital - Defense World
Invivyd seeks FDA nod for COVID-19 treatment in immunocompromised By Investing.com - Investing.com Australia
Invivyd's (IVVD) Buy Rating Reiterated at D. Boral Capital - MarketBeat
Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA's Gating Request for Completing Its Review of EUA Request for PEMGARDA™ (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromi - The Manila Times
Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA’s Gating Request for Completing Its Review of EUA Request for PEMGARDA™ (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromi - Yahoo Finance
Invivyd, Inc. (NASDAQ:IVVD) Shares Bought by Barclays PLC - Defense World
Invivyd (NASDAQ:IVVD) vs. iTeos Therapeutics (NASDAQ:ITOS) Head-To-Head Comparison - Defense World
D. Boral Capital Reiterates Buy Rating for Invivyd (NASDAQ:IVVD) - Defense World
What's Going On With COVID-19 Antibody Developer Invivyd Stock On Friday? - Yahoo Finance
Invivyd (NASDAQ:IVVD) Receives "Buy" Rating from D. Boral Capital - MarketBeat
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC - The Manila Times
Invivyd's PEMGARDA Shows Powerful Defense Against Dominant COVID Variant XEC in Latest Data - StockTitan
Barclays PLC Raises Stake in Invivyd, Inc. (NASDAQ:IVVD) - Defense World
Why Invivyd, Inc. (IVVD) Is Among the Best Penny Stocks to Invest In According to Media? - Yahoo Finance
12 Best Penny Stocks to Invest in According to the Media - Insider Monkey
Invivyd Inc Stock (IVVD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Invivyd Inc Stock (IVVD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MCGUIRE TERRANCE | Director |
Dec 27 '24 |
Sale |
0.52 |
83,744 |
43,647 |
3,256,776 |
| MCGUIRE TERRANCE | Director |
Dec 30 '24 |
Sale |
0.48 |
86,545 |
41,784 |
3,170,231 |
| MCGUIRE TERRANCE | Director |
Dec 20 '24 |
Sale |
0.42 |
119,805 |
50,725 |
3,568,274 |
| MCGUIRE TERRANCE | Director |
Dec 26 '24 |
Sale |
0.54 |
83,817 |
45,563 |
3,340,520 |
| MCGUIRE TERRANCE | Director |
Dec 24 '24 |
Sale |
0.51 |
68,161 |
34,503 |
3,424,337 |
| MCGUIRE TERRANCE | Director |
Dec 23 '24 |
Sale |
0.45 |
75,776 |
34,076 |
3,492,498 |
1.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):